Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A novel at-home device using 40 Hz light and sound stimulation to treat Alzheimer's failed to meet its primary endpoint in the pivotal HOPE trial. However, a prespecified subgroup of patients with mild Alzheimer's showed meaningful slowing of decline in daily function and disease severity. Cognito Therapeutics says it plans to pursue FDA approval based on those encouraging signals.
A pivotal clinical trial of Cognito Therapeutics' Spectris device — which delivers daily 40 Hz light and sound stimulation to engage gamma-frequency brain activity — did not meet its primary endpoint in patients with mild-to-moderate Alzheimer's disease. In the overall study population of 663 participants, there was no significant difference between the active device and sham on a composite measure of cognition and daily function at 12 months.
But the story doesn't end there. A prespecified subgroup of 395 patients with mild Alzheimer's (MMSE scores 21–28) showed nominally significant slowing of decline — 56% on daily functioning (ADCS-ADL) and 47% on disease severity (CDR-SB) compared to sham. Patients with moderate disease saw no benefit, suggesting that earlier intervention may be critical. Cognito plans to engage the FDA about a De Novo submission for early symptomatic Alzheimer's.
Key Takeaways
Why it matters: Unlike drug-based therapies, Spectris is non-invasive, home-use, and carries no risk of ARIA — a serious side effect seen with antiamyloid drugs. If further evidence confirms benefit in early-stage patients, this device could offer a complementary, lower-risk option in the Alzheimer's treatment toolkit.